



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/341,821	09/01/1999	MICHAEL J. WARING	CV0244	5635
7590 06/19/2008				
T R FURMAN BRISTOL MYERS SQUIBB COMPANY 100 HEADQUARTERS PARK DRIVE SKILLMAN, NJ 08558			EXAMINER GHALL, ISIS A D	
			ART UNIT	PAPER NUMBER
			1611	
			MAIL DATE	DELIVERY MODE
			06/19/2008 PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

09/341,821

**Applicant(s)**

WARING ET AL.

**Examiner**

Isis A. Ghali

**Art Unit**

1611

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 11 April 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 5, 6, 8-10, 14, 15 and 18-20 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 5, 6, 8-10, 14, 15 and 18-20 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/C)
- 4) ☐ Interview Summary (PTO-413)
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_
- Paper No(s)/Mail Date \_\_\_\_\_

### **DETAILED ACTION**

The receipt is acknowledged of applicants' request for RCE filed 04/11/2008; and amendment after final filed 02/28/2008.

Claims 5, 6, 8-10, 14, 15, 18-20 are pending and included in the prosecution.

#### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 04/11/2008 has been entered.

#### ***Claim Rejections - 35 USC § 103***

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 5, 6, 8-10, 14, 15, 18-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teachings of EP 0 666 081 ('081), US 3,788,521 ('521) and US 3,976,223 ('223).

EP '081 teaches gel wound dressing comprising material comprising:

- a) from about 0.05% to 10% by weight of natural gelling agent;
- b) from about 1.0% to 10% by weight of hydrocolloid;
- c) from about 5.0% to 30.0% by weight of an alkylene glycol and
- d) at least 50% by weight of water.

Therefore, EP '081 teaches the gel wound dressing composition as claimed by claim 5. The gel composition of the reference can be extruded in the form of gel through a nozzle (page 2, lines 20-24; page 3, lines 14-18). The gel of the reference has viscosity of 50-800 Pas, as required by claim 18, (page 2, lines 54-55). The reference disclosed the gel conforms readily to the shape of the wound particularly when the

wound includes a cavity, and that teaching suggests treating wound of sinus cavities (page 2, lines 8-9). The wound dressing is packaged and sterilized, as required by claims 6, 10 and 15.

Although EP '081 teaches delivery of gel wound dressing from a nozzle, it does not teach delivery of the gel wound dressing from aerosol barrier.

US '521 teaches pressurized aerosol package comprises rigid container having dispensing valve, and collapsible container inside the rigid container and pressurized gas, i.e. positive pressure, filled in between the two containers (abstract; col.3, lines 33-40, figures). The pressurized container is self-sealing according to applicants' definition to self-sealing in page 2, lines 14-21: "because there is positive pressure in the container, the vessel can be made self sealing. This aids maintenance of product sterility". The aerosol package is made large enough to provide multiplicity of one-shot applications (col.10, lines 43-44), i.e. multi-doses. Therefore, the pressurized aerosol disclosed by the reference is self-sealing and provides sterile multiple doses. Applicants disclosed at page 3, lines 34-36 that the aerosol vessel disclosed by US '521 is one of the preferred aerosol vessel used to deliver the gel of the present invention. US '521 teaches that the discharged product from the aerosol has a uniform density and maintained a predetermined physical characteristic all the life of the package (col.7, lines 47-52; col.10, lines 35-38). US '521 disclosed method for assembling the package including the steps of filling the outer container with a gas, filling the inner container with the product, followed by inserting a valve on the neck of the containers with a press fit (col.12, lines 41-53).

However, US '521 does not teach delivering gel from the disclosed aerosol package.

US '223 teaches an aerosol container containing gel comprising carboxymethyl cellulose, gelling agent and alginate. The gel comprises polyethylene glycol, which reads on gelling agent and alkylene glycols claims by claim 5 (col.6, lines 28-31, 34, 48, 63-65; col.7, lines 29-30; col.9, lines 20-23, 45-48, 51-55). The aerosol containing gel used to treat burns, which reads on wound (col.9, lines 20-55). Therefore, the art recognized at the time of the invention that wound dressing gel can be delivered from an aerosol package. The aerosol is provided by mechanical stream break up features, i.e. self-sealing (col.2, lines 65-67). The aerosol disclosed by the reference is not a single dose container as implied by the effort made to avoid contamination of the contents during use.

Therefore, it would have been obvious to one having ordinary skill in the art at the time of the invention to provide wound dressing gel deliverable from a nozzle for treating cavities comprising natural gelling agent, hydrocolloid, alkylene glycol and water as disclosed by EP '081, and one having ordinary skill in the art knowing that wound dressing gels can be delivered from an aerosol package as disclosed by US '223 would have been motivated to replace the delivery means that have a nozzle with an aerosol package, and further use the aerosol package disclosed by US '521 having inner and outer container separated by pressurized gas, motivated by the teaching of US '521 that the discharged product from such as aerosol has a uniform density and maintained a predetermined physical characteristic all the life of the package, with reasonable

expectation of having wound dressing gel delivered from an aerosol package having inner container and outer container separated by a pressurized gas and meanwhile the delivered gel will have a uniform density and maintain a predetermined physical characteristic all the life of the package.

The combined teaching of the references implies method of delivery of the wound dressing gel into the wound as required by claim 15.

Regarding claims 6, 9, 10, 15, 19 and 20 that require sterilization of the gel, it is obvious to one having ordinary skill in the art at the time of the invention to sterilize any wound dressing before application to the wound to avoid contamination of the tissue already compromised by the existing wound, with reasonable expectation to accomplish the step of sterilization of the gel composition prior or after loading into the aerosol container to obtain barrier aerosol containing sterile gel that can be applied safely to the tissue without pain with avoidance of contamination of tissue already compromised by the wound or burn. Additionally, the content of the pressurized aerosol disclosed by US '521 is expected to maintain sterility of its contents if it is sterilized because according to applicants' definition to self-sealing in page 2, lines 14-21: "because there is positive pressure in the container, the vessel can be made self sealing. This aids maintenance of product sterility". Therefore, pressurized aerosol container maintains the sterility of its content after each discharge due to the positive pressure.

Regarding claim 14 that teaches treating sinuses, one having ordinary skill in the art will be motivated to use the gel composition delivered by aerosol of the combined teachings of the references to treat sinuses because EP '081 suggested delivering the

wound dressing gel to the body cavities, and that encompasses sinuses cavities, and one having ordinary skill in the art would have been motivated to use the aerosol because US '223 teaches aerosol gel is protected from contamination, and US '521 teaches that products delivered from pressurized aerosol will have a uniform density and maintain a predetermined physical characteristic all the life of the package.

### ***Response to Arguments***

5. Applicant's arguments filed 02/28/2008 have been fully considered but they are not persuasive. Applicants argue that:

- Although '081 does disclose a gel, '081 does not disclose a method of, and a vessel, for safely and efficiently dispensing multiple doses of wound-treating gel where the gel is in gel form in the container, and the vessel's self-sealing characteristic minimizes the contamination of the gel after the use of the vessel.
- Applicants argue that the purpose of the package of '223 is to separately store a plurality of flowable substances in a single package from which such substances may be dispensed. US '223 teaches only the lower chamber of the outer container is pressurized with a gas through a self-sealing plug in the container bottom. Since only the lower chamber of the outer container of '223 is pressurized with a gas through a self-sealing plug, the container in '223 is not self-sealing as required in the rejected claims. US '223 does not address the avoidance of contamination during use, only with respect to storage.
- Applicants argue that the addition of '521 does not make up for the deficiencies of the other two documents. It is cited in the specification as showing one example of the general "type" of vessel used. However, as noted in the action, '521 does not teach delivering gel.



- Applicants argue that combination of the references cannot teach the invention to one of ordinary skill in the art.

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). In this case, the rejection is based on the combined teachings of EP '081, US '521 and US '223. As applicants themselves admit, the claimed gel composition is disclosed by EP '081. The only difference between the reference and the present claims is the packaging of the present gel composition and its delivery from an aerosol. EP '081 suggests coating a fibrous material with a gel extruded from a nozzle. EP '81 disclosed the gel composition is sterilized and autoclaved without destruction.

US '223 is relied upon for teaching gel can be delivered from a pressurized aerosol container. US '223 is interested in making gel in aerosol for spraying. US '223 solved problem of keeping reactive components that may interfere with one another prior to application apart until dispersion from the container. It necessary follows from the teaching of EP '081 and US '223 that one would use single compartment vessel when there was no issue of reactivity or degradation of components of the composition.

Therefore, US '521 was involved in the rejection for teaching aerosol container having single inner and single outer container separated by pressurized gas, because US '521 teaches that the discharged product from such as aerosol has a uniform

density and maintained a predetermined physical characteristic all the life of the package.

Additionally, the dispensing valve disclosed by US '223 is kept shut with a compression spring [30] that prevents the flowable materials present in the containers from entering into the exit passageway, col.3, lines 28-47. The exit ports are opened by depressing the compression spring to actuate the dispensing valve, col. 4, lines 35-40. Once actuated, the "the gas under pressure in pressure tight chamber B" forces the piston upward, pushing the flowable materials through the exit passageway and out through the dispensing valve, col.4, lines 38-45. As a result, "a uniform, metered amount of the flowable material" is discharged from the package, col.4, lines 46-58. US '223 indicates that "dispensing valve assembly" forms "a pressure tight closure when the valve is closed, col.3, lines 20-24. This structure described by US '223 can be characterized as "self-sealing" since the compression spring [30] in combination with the lower pressurized container keep the valve shut. US '223 states that the "relative metering" of the flowable material from the container "is constant throughout the life of the dispenser," indicating that it contains "multiple doses," as required by claim 1, col.4, line 66-col.5, line 2. Further, self sealing valve disclosed by US '223 reads on the present self-sealing in light of applicants' disclosure and figure 1 that set forth two meaning for self-sealing, and one of them is the valve in the bottom of the container used to fill the container with the pressurized gas.

In considering the disclosure of the reference, it is proper to take into account not only the specific teachings of the reference but also the inferences which one skilled in

the art would reasonably be expected to draw therefrom. *In re Preda*, 401 F.2d 825, 826, 159 USPQ 342, 344 (CCPA 1968). The rational to modify or to combine the prior art does not have to be expressly stated in the prior art; the rational may be expressly or impliedly contained in the prior art or it may be reasoned from knowledge generally available to one of ordinary skill in the art. The reason or motivation to modify the reference may often suggest what the inventor has done, but for a different purpose or to solve different problem. It is not necessary that the prior art suggest the combination or modification to achieve the same advantage or result discovered by applicant. *In re Linter*, 458 F.2d 1013, 173 USPQ 560 (CCPA 1972). A conclusion of obviousness under 35 U.S.C. 103 (a) does not require absolute predictability, only a reasonable expectation of success; and references are evaluated by what they suggest to one versed in the art, rather than by their specific disclosure. *In re Bozek*, 163 USPQ 545 (CCPA 1969).

In response to applicant's argument that the combination of the references does not teach the invention to one having ordinary skill in the art, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, it would have been obvious to one having ordinary skill in the art at the time of the invention to provide wound dressing gel deliverable from a nozzle

for treating cavities comprising natural gelling agent, hydrocolloid, alkylene glycol and water as disclosed by EP '081, and one having ordinary skill in the art knowing that wound dressing gels can be delivered from an aerosol package as disclosed by US '223 would have been motivated to replace the delivery means that have a nozzle with an aerosol package, and further use the aerosol package disclosed by US '521 having inner and outer container separated by pressurized gas, motivated by the teaching of US '521 that the discharged product from such as aerosol has a uniform density and maintained a predetermined physical characteristic all the life of the package, with reasonable expectation of having wound dressing gel delivered from an aerosol package having inner container and outer container separated by a pressurized gas and meanwhile the delivered gel will have a uniform density and maintain a predetermined physical characteristic all the life of the package.

It has been held that "When a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious." *KSR Int 'l Co. v. Teleflex Inc.*, 127 S.Ct. 1727, 1740 (2007) (quoting *Sakraid v. AG Pro, Inc.*, 425 U.S. 273,282 (1976)). "When the question is whether a patent claiming the combination of elements of prior art is obvious," the relevant question is "whether the improvement is more than the predictable use of prior art elements according to their established functions."

In the light of the foregoing discussion, the Examiner's ultimate legal conclusion is that the subject matter defined by the claims would have been *prima facie* obvious within the meaning of 35 U.S.C. 103 (a).

6. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US 5,976,573 teaches pharmaceutical composition in the form of gel that can be sprayed into the nasal cavity including nasal sinuses, such a gel composition has relatively high viscosity between 400 to 1000 cp such that resists being cleared from the mucosal surfaces and remains on the mucosal surfaces for relatively long periods of time (abstract; col.4, lines 38-41, 60-62; col.11, lines 15-20; claim 21 and 34). The gel is sprayed using aerosol container comprises multiple doses (col.8, lines 33-38; col.9, lines 26-31). The gel composition comprises a 5-15% suspending agent including carboxymethyl cellulose that read on hydrocolloid, dispersing agent including Pluronic that reads on gelling agent and alkylene glycols, and water (col.5, lines 30-35, 67; col.6, line 1).

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Isis A. Ghali whose telephone number is (571) 272-0595. The examiner can normally be reached on Monday-Thursday, 6:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone

Art Unit: 1611

number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

IG

/Isis A Ghali/  
Primary Examiner, Art Unit 1611